Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Eupraxia Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2026 was C$-250.02 Mil.
Eupraxia Pharmaceuticals's quarterly retained earnings
declined
from Sep. 2025 (C$-211.48 Mil) to Dec. 2025 (C$-233.94 Mil) and
declined
from Dec. 2025 (C$-233.94 Mil) to Mar. 2026 (C$-250.02 Mil).
Eupraxia Pharmaceuticals's annual retained earnings
declined
from Dec. 2023 (C$-141.54 Mil) to Dec. 2024 (C$-186.64 Mil) and
declined
from Dec. 2024 (C$-186.64 Mil) to Dec. 2025 (C$-233.94 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Eupraxia Pharmaceuticals Retained Earnings Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of C$-250.02 Mil mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Retained Earnings of C$-250.02 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Eupraxia Pharmaceuticals and its competitors.
Is Eupraxia Pharmaceuticals' Retained Earnings too high?
Eupraxia Pharmaceuticals' current Retained Earnings is C$-250.02 Mil. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Retained Earnings compare to VRTX and REGN?
Eupraxia Pharmaceuticals' Retained Earnings of C$-250.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current Retained Earnings is C$-250.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Retained Earnings of C$-250.02 Mil. The current Retained Earnings is C$-250.02 Mil. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Retained Earnings is C$-250.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score
Get the complete analysis for TSX:EPRX
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EPRX has been successfully added to your 
